A growing number of experts are questioning AstraZeneca’s claims about Brilinta (ticagrelor), a blood thinner widely prescribed for acute coronary syndrome. Allegations suggest the company misrepresented clinical trial data, concealing Brilinta’s limited efficacy and potential to increase heart attack risk. Critics call this a dangerous betrayal of trust—one that may have put millions at risk while profiting Big Pharma. Independent reviews urge reevaluation of the drug’s safety profile.
AstraZeneca’s Brilinta heart drug found ineffective in new analysis, may raise heart attack risk.
